Safety and Efficacy of Fruquintinib Plus Chidamide and Sintilimab in the Third and Later Line Treatment of MSS/pMMR Metastatic Colorectal Cancer

The prognosis of most patients with unresectable locally advanced or metastatic colorectal cancer (CRC) remains poor despite the advancements in chemotherapy and target therapy. CAPability-01 trial investigated the potential efficacy of combining the programmed cell death protein-1 (PD-1) monoclonal antibody sintilimab with the histone deacetylase inhibitor (HDACi) chidamide with or without the anti-vascular endothelial growth factor (VEGF) monoclonal antibody bevacizumab in patients with unresectable chemotherapy-refractory locally advanced or metastatic microsatellite stable/proficient mism

Trial Details

NCT ID
NCT06685276
Phase
PHASE2
Sponsor
Dai, Guanghai
Status
RECRUITING
Cancer Type
Colorectal Cancer
Interventions
  • Fruquintinib
  • Sintilimab
  • Chidamide
Locations (sample)
  • Beijing, China|39.9075,116.39723

Key Eligibility Criteria

  • Fully understand this study and voluntarily sign the informed consent form;
  • Age between 18-75 years inclusive;
  • Patients with histologically confirmed unresectable locally advanced, recurrent, or metastatic colorectal adenocarcinoma;
  • Failure of standard second-line systemic treatment with measurable lesions;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colorectal Cancer Trials on Trialify →